Stock & Company Details
Fate Therapeutics Inc $FATE
Price:
46,691,331
117M
$326M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-3.26
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
FATE technical indicators
Latest Fate Therapeutics Inc (FATE) indicator readings as of 2026-08-10.
FATE's 14-day RSI is 56.8, in neutral territory. At $2.76 it is trading 72.2% above its 200-day moving average of $1.60, and above its 50-day average of $2.48. Price sits in the middle of its Bollinger Bands ($2.23 to $3.01). ADX reads 16.6, indicating a range-bound market rather than a trend.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Finance Bot
Ask your questions
Start by typing a question below.
